Loading...
Loading...
Browse all stories on DeepNewz
VisitEli Lilly Cuts Zepbound Price by 50%, Impacting Hims Stock and Earning Biden's Praise
Aug 27, 2024, 03:28 PM
Eli Lilly has announced a significant price reduction for its weight-loss drug Zepbound, now offering single-dose vials at a 50% discount. This move aims to expand access to the drug, particularly for patients without insurance coverage. The discounted vials are available through Lilly's direct-to-consumer platform, LillyDirect, with prices set at $399 for a four-week supply of the 2.5 mg dose and $549 for the 5 mg dose. This initiative is part of Eli Lilly's strategy to address supply shortages and increase the availability of Zepbound amid rising demand. The price cut poses a challenge to telehealth companies that offer compounded versions of the medication. In response to the announcement, shares of Hims & Hers Health fell, reflecting the competitive impact of Lilly's strategy. Additionally, President Biden praised the price reduction as a positive step towards making medications more affordable.
View original story
Markets
No • 50%
Yes • 50%
Market share reports from reputable market research firms like Statista or MarketWatch
No • 50%
Yes • 50%
Closing stock price of Eli Lilly on a publicly available financial platform like Yahoo Finance or Bloomberg
Yes • 50%
No • 50%
Closing stock price of Hims & Hers Health on a publicly available financial platform like Yahoo Finance or Bloomberg
No significant change in patient access • 25%
Significant increase in patient access • 25%
Decrease in patient access • 25%
Moderate increase in patient access • 25%
Reports from healthcare research firms and Eli Lilly's own data releases
No significant change • 25%
Eli Lilly loses market share • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Market share reports from reputable market research firms like Statista or MarketWatch
Above $12 billion • 25%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Eli Lilly's Q4 2024 financial report